– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –

See the rest here:
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

See the original post here:
Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time

Original post:
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the recent increase in market activity.

Visit link:
Unaware of Any Undisclosed Material Change

Sandusky, OH, Oct. 15, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed shipping its first CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ).

See more here:
PAOG Confirms Monday Marketing Launch Of First CBD Product Targeting $100 Billion Market

Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1?1%, as determined by an FDA-approved test.

Read more:
US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Media ReleaseCopenhagen, Denmark, October 15, 2021

Read this article:
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer...

Ad hoc announcement pursuant to Art. 53 LR

Follow this link:
Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress

LEXINGTON, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twenty new employees.

Visit link:
T2 Biosystems Reports Granting of Inducement Award

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.

Follow this link:
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021